References
- Chen D, Misra A, Garg A. Clinical review 153: Lipodystrophy in human immunodeficiency virusinfected patients. J Endocrinol Metab 2002; 87: 4845–56.
- Ritt MJPF, Hillebrand-HaverKort ME, ten Veen JH. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy. Acta Chirurgiae Plasticae 2001; 43: 54–56.
- Wig N. Antiretroviral therapy: are we aware of adverse effects? J Ass Physicians India 2002; 50: 1163–71.
- Walther RA. Facial lipoystrophy in patients with HIV infections troublesome to treat. Lakartidningen 2002; 99: 3826–9.
- Garcia-Viejo MA, Ruiz M, Martinez E. Strategies for treating HIV-related lipoystrophy. Expert Opin Investig Drugs 2001; 10: 1443–56.
- Talmor M, Hoffman LA, La Trenta GS. Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction. Ann Plast Surg 2002; 49: 11–17.
- Pacini S, Ruggiero M, Cammarota N, Protopapa C, Gulisano M. Bio-Alcamid, a novel prosthetic polymer, does not interfere with with morphological and functional characteristics of human skin fibroblasts. Plast Reconstr Surg 2003; 111: 489–91.
- Fagien S. Facial soft tissue augmentation with injectable autologous and allogenic human tissue collagen matrix (autologen and dermalogen). Plast Reconstr Surg 2000; 105: 362.
- Naoum C, Dasiou-Plakida D. Dermal filler materials and botulin toxin. Int J Dermatol 2001; 40: 609–621.
- Maas CS, Papel ID, Greene D, Stoker DA. Complications of injectable synthetic polymers in facial augmentation. Dermatol Surg 1997; 23: 871–877.
- Levan P, Ngnuyen TH, Lallemand F, et al. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS 2002; 16: 1985–7.
- Pacini S, Ruggiero M, Morucci G, Cammarota N, Protopapa C, Gulisano M. Bio-Alcamid: a novelty for reconstructive and cosmetic surgery. Ital J Anat Embryol 2002; 107: 209–214.